Addition of low-dose or very low-dose spironolactone reduced morning home systolic blood pressure by 8.2 to 13.0 mmHg across patients on CCB, ACEI, or ARB monotherapy.
Observational (n=86)
Does low-dose or very low-dose spironolactone reduce morning home blood pressure in uncontrolled hypertensive patients on monotherapy?
Addition of low-dose or very low-dose spironolactone effectively reduces home blood pressure in patients with uncontrolled hypertension on monotherapy, though serum potassium requires monitoring.
Low-dose (25 mg) or very low-dose (12.5 mg) spironolactone were added among 86 uncontrolled hypertensive patients who were undergoing monotherapy with calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin AT1-receptor blockers (ARBs). Morning home systolic/diastolic blood pressure (BP) reduction was similar among the CCB (n = 30, -8.2/-2.6 mmHg), ACEI (n = 22, -13.0/-4.7 mmHg), and ARB (n = 34, -11.5/-5.1 mmHg) groups. An increase in serum potassium correlated positively with the decline in morning systolic BP. Even very low-dose (12.5 mg) spironolactone is clinically effective, although serum potassium should be carefully monitored.
Hanazawa et al. (Thu,) conducted a observational in Essential Hypertension (n=86). Spironolactone was evaluated on Morning home systolic/diastolic blood pressure reduction. Addition of low-dose or very low-dose spironolactone reduced morning home systolic blood pressure by 8.2 to 13.0 mmHg across patients on CCB, ACEI, or ARB monotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: